ALNY Earnings

Quarterly EPS
$-0.87
Q3 2024
$-0.65
Q4 2024
$-0.14
Q1 2025
$-0.55
Q2 2025
$1.91
Q3 2025
$1.41
Q4 2025
$1.55
Q1 2026
$1.23
Q2 2026
Latest Revenue1.3B
Latest Net Income164.5M
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026$1.231.3B164.5M+66.9%+323.6%
Q1 2026$1.551.2B206.0M+96.4%+1,207.1%
Q4 2025$1.411.1B186.4M+84.9%+316.9%
Q3 2025$1.911.2B251.1M+149.3%+319.5%
Q2 2025-$0.55773.7M-72228000+17.3%-323.1%
Q1 2025-$0.14594.2M-18251000+20.2%+73.1%
Q4 2024-$0.65593.2M-83763000+34.9%+40.9%
Q3 2024-$0.87500.9M-111570000-33.3%-173.7%
Q2 2024-$0.13659.8M-16889000
Q1 2024-$0.52494.3M-65935000
Q4 2023-$1.10439.7M-137870000
Q3 2023$1.18750.5M147.8M
Alnylam Pharmaceuticals (ALNY) — Earnings